Axa
CRL icon

Axa’s Charles River Laboratories CRL Stock Holding History

Axa’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,499
Closed -$683K – 300
2025
Q2 		$683K Buy
+4,499
New +$600K ﹤0.01% 954
2021
Q3 		– Sell
-12,200
Closed -$4.51M – 1244
2021
Q2 		$4.51M Sell
12,200
-2,200
-15% -$735K 0.01% 734
2021
Q1 		$4.17M Buy
14,400
+12,400
+620% +$3.45M 0.01% 740
2020
Q4 		$500K Buy
2,000
+700
+54% +$167K ﹤0.01% 1068
2020
Q3 		$294K Hold
1,300
– – ﹤0.01% 1112
2020
Q2 		$227K Buy
+1,300
New +$207K ﹤0.01% 1160
2014
Q4 		– Sell
-700
Closed -$42K – 1422
2014
Q3 		$42K Sell
700
-23,000
-97% -$1.32M ﹤0.01% 1364
2014
Q2 		$1.27M Hold
23,700
– – 0.01% 873
2014
Q1 		$1.43M Sell
23,700
-200
-0.8% -$11.7K 0.01% 851
2013
Q4 		$1.27M Buy
+23,900
New +$1.2M 0.01% 866

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Axa's CRL Position: Q3 2025 in Review

Axa sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 4,499 shares — an estimated $683K sold.

Axa first reported a position in CRL in Q4 2013 and held it in 10 quarters. The position peaked at $4.51M in Q2 2021. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Axa reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • Axa sold 4,499 Charles River Laboratories shares in Q3 2025, an estimated $683K.
  • Axa first reported a position in Charles River Laboratories in Q4 2013 and held it in 10 quarters.
  • Axa's Charles River Laboratories position peaked at $4.51M in Q2 2021.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.